Pawel Dobrzanski

TL;DR: It is found that lestaurtinib inhibits the growth of HEL92.1.7 cells, which are dependent on mutant JAK2 activity for growth in vitro and in xenograft models, and therefore holds promise as a therapeutic agent for patients with these disorders.

TL;DR: It is shown that members of the mixed-lineage kinase (MLK) family are expressed in neuronal cells and are likely to act between Rac1/Cdc42 and MKK4 and -7 in death signaling, and findings place the MLKs upstream of mitochondrial cytochromec release and caspase activation.

TL;DR: It is reported that interfering with EphA signaling resulted in a pronounced inhibition of angiogenesis in ex vivo and in vivo model systems and provides a strong rationale for targeting E phA2 receptors for anticancer therapies.

TL;DR: Together, these data link the SAPK/JNK pathway and multiple biochemical events associated with Aβ‐induced neuronal death and further delineate the point of CEP‐1347 interception within this signal transduction cascade.

TL;DR: Evaluation of the antiangiogenic activity of CEP-5214 revealed a dose-related inhibition of microvessel growth ex vivo in rat aortic ring explant cultures and in vitro on HUVEC capillary-tube formation on Matrigel at low nanomolar concentrations, which resulted in significant inhibition in the growth of a variety of established murine and human s.o.c. tumor xenografts.